This upcoming webinar will look at potential issues in LC-MS/MS analysis of large clinical panels, with an emphasis on the impact of matrix components for a variety of biological sample types.

When is it happening?

Date: 19 May, 2020

Start Times:
Broadcast #1: 10 am BST (London) / 11 am CEST (Paris)

Broadcast #2: 10 am PDT (California) / 1 pm EDT (New York)

By combining LC-MS/MS system sensitivity with modern ultra high-pressure liquid chromatography (UHPLC), the necessity for high-purity components and samples is increasingly apparent. The choice of sample preparation technique varies between labs and is generally dependent on several factors: operator familiarity; technique complexity; price per sample; instrument sensitivity; assay sensitivity and limits of quantitation; sample volume; throughput; analyte functionality and target matrix.

This webinar will discuss typical clinical matrices, such as whole blood, plasma, serum, urine and oral fluid, with specific emphasis on a variety of endogenous components. Matrix complexity will be illustrated and related to a variety of clinical assays, demonstrating potential impact on method robustness. Examples will be presented detailing challenges involved for large panel analysis.

By attending this webinar you will be provided with ...

  • an introduction to individual matrix components for a variety of biological sample types and potential issues in LC/MS analysis
  • consideration of sample preparation technique when dealing with cross-functional analytes in clinical assays

The Presenter

DrWilliamsLee Williams Ph.D (Biotage GB Limited)
Lee gained a Ph.D in mass spectrometry under the tutorship of Prof. David E. Games from the University of Wales, Swansea in 2000. He went on to complete a Post-Doc in the Biochemical Toxicology department at the National Center for Toxicological Research, FDA labs in Arkansas, USA. In 2004 he returned to Wales to join Biotage (Formerly Argonaut) to advance the LC/MS capability within the sample preparation arena. Over the 16 years he has occupied a variety of roles from senior scientist, group leader, lab manager and most recently Director of R&D for Analytical Consumables and Applications.

Published  May 5, 2020

Home 9 Bioclinical 9 Minimizing matrix effects & maximizing recoveries in clinical assays